Oncology Central

From linear ‘dogma‘ and trastuzumab–emtansine to future transcriptional circuitry-based drug discovery for breast cancer


Almost six decades have been spent by researchers and clinicians, after the DNA double helix discovery, on the simple transcription concept of a single gene–phenotype linear approach. All currently available drugs, including targeted agents, against a single genetic abnormality [1], are based on this idea established by Crick in 1958 [2]. However, the transcriptional process is far more complicated [3], with recent evidence for transcriptional circuitry driving genes and cell function.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.